-
Roth Capital Reiterates Buy Following Conatus Pharmaceuticals (CNAT) Phase II Emricasan Data
-
Conatus Pharmaceuticals (CNAT) Bullish Stance Reiterated at Roth Capital Following Data
-
Conatus Announces Completion of Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
-
Conatus Announces Completion of Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
-
Conatus Pharmaceuticals (CNAT) Prices 3.5M Common Offering at $5.75/Share
-
Conatus Announces Pricing of Public Offering of Common Stock
-
Conatus Announces Pricing of Public Offering of Common Stock
-
Conatus Pharmaceuticals (CNAT) Falls on Plans to Offer Common Stock
-
Conatus Announces Proposed Public Offering of Common Stock
-
Conatus Announces Proposed Public Offering of Common Stock
-
Roth Capital Reinstates Conatus Pharmaceuticals (CNAT) at Buy
-
Unusual 11 Mid-Day Movers 06/20: (KMX) (FLML) (CARA) Higher; (MACK) (PVCT) (CLRX) Lower
-
Pre-Open Stock Movers 6/13: (OPEN) (EXPR) (ICLD) Higher; (FNSR) (OCLS) (ETRM) Lower (more...)
-
Roth Capital Starts Conatus Pharmaceuticals (CNAT) at Buy
-
Notable Analyst Rating Changes 03/07: (GTAT) (CCRN) (PRU) Upgraded; (ALU) (NMRX) (VMEM) Downgraded
-
Roth Capital Starts Conatus Pharmaceuticals (CNAT) at Buy

